Rachel Humphrey has spent over 25 years in drug development. Currently, she serves as President and Founding CEO of Normunity. Highlights of her career include oversight of the development of Yervoy® (ipilimumab; BMS), Imfinzi® (durvalumab; AZ), and Nexavar® (sorafenib; Bayer). CMO roles at Black Diamond Therapeutics, CytomX Therapeutics and Mirati Therapeutics followed thereafter. She previously served as an Independent member of the Board of Directors at CytomX Therapeutics and Xilio Therapeutics, respectively, and currently serves on the Board of Directors of Pyxis Therapeutics, Sporos Bioventures, and Voro Therapeutics, respectively. Her education includes a BA from Harvard, MD at Case Western Reserve, Internal Medicine at Johns Hopkins, and Oncology at the NCI.